Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

BACKGROUND: To date, only monoclonal antibodies have been shown to be effective for outpatients with COVID-19. Interferon lambda-1 is a type III interferon involved in innate antiviral responses with activity against respiratory pathogens. We aimed to investigate the safety and efficacy of peginterf...

Descripción completa

Detalles Bibliográficos
Autores principales: Feld, Jordan J, Kandel, Christopher, Biondi, Mia J, Kozak, Robert A, Zahoor, Muhammad Atif, Lemieux, Camille, Borgia, Sergio M, Boggild, Andrea K, Powis, Jeff, McCready, Janine, Tan, Darrell H S, Chan, Tiffany, Coburn, Bryan, Kumar, Deepali, Humar, Atul, Chan, Adrienne, O'Neil, Braden, Noureldin, Seham, Booth, Joshua, Hong, Rachel, Smookler, David, Aleyadeh, Wesam, Patel, Anjali, Barber, Bethany, Casey, Julia, Hiebert, Ryan, Mistry, Henna, Choong, Ingrid, Hislop, Colin, Santer, Deanna M, Lorne Tyrrell, D, Glenn, Jeffrey S, Gehring, Adam J, Janssen, Harry L A, Hansen, Bettina E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906707/
https://www.ncbi.nlm.nih.gov/pubmed/33556319
http://dx.doi.org/10.1016/S2213-2600(20)30566-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906707/
https://www.ncbi.nlm.nih.gov/pubmed/33556319
http://dx.doi.org/10.1016/S2213-2600(20)30566-X

Ejemplares similares